Novo Nordisk offers discounted Wegovy subscription

Novo Nordisk is introducing a new subscription program for its Wegovy obesity drugs, aiming to attract customers with a more affordable and predictable monthly cost. This initiative seeks to make the treatment more accessible and competitive in the growing weight-loss drug market. The company's strategy focuses on patient retention and market share expansion by addressing cost barriers associated with long-term medication use.